JavaScript seem to be disabled in your browser.
You must have JavaScript enabled in your browser to utilize the functionality of this website.
Olokizumab is a clinical stage anti-IL-6 monoclonal antibody, that was designed for potential to treat autoimmune diseases. The antibody blocks assembly of the hexameric IL-6/IL-6 α-receptor/gp130 (IL6ST) complex that is required for signal transduction.